OncoHost: Funding, Investors & Team (Sep 2026)
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy. The company utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today's resistance to therapy. Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners. OncoHost's platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and the discovery of new targets to overcome treatment resistance. OncoHost was founded in 2017 and is headquartered in Binyamina, Israel.
OncoHost has raised $43.0M across 2 funding rounds on record, the most recent a Series C of $35.0M announced in May 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
OncoHost Company Profile and Key Stats
Latest funding round on record: May 2022.
OncoHost Funding Rounds
OncoHost raised $8.0M in a Series B announced in Jan 2021.
1.3 years later, a Series C of $35.0M was announced in May 2022.
OncoHost Founders and Leadership Team
Contact details for the OncoHost team: 1 of 2 have an email address on file.
Start 14-day free trial →OncoHost Funding Compared to Other Biotechnology Startups
OncoHost's latest round of $35.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like OncoHost in Biotechnology and Binyamina
Companies Similar to OncoHost
CollPlant is a regenerative medicine company that focuses on 3D bioprinting of tissues and organs and also…
Magdent’s novel technology utilizes electromagnetic fields, PEMF technology, to stimulate, accelerate, and…
Brevel has created an innovative method of cultivating microalgae that is both sustainable and…
RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company primarily focused on…
Regentis Biomaterials is a privately held company focused on developing and commercializing proprietary…
IceCure Medical is a medical device company setting new standards in minimally-invasive tumor therapy for…
Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing…
Phytolon is transforming the process of creating food colors by using an innovative and environmentally…
BlueWind Medical develops and markets a wireless neurostimulation device for the treatment of peripheral…
SuperMeat is an Israeli bio-tech and food-tech organization, fostering an innovation to make clean meat from…
ECOncrete technology provides sustainable solutions for construction of ecologically active infrastructures,…
MSICS Pharma is a pharmaceutical company that manufactures and produce naturally-sourced Psilocybin for…
OncoHost Funding FAQs
What does OncoHost do?
OncoHost is a clinical-stage biotechnology company developing personalized strategies to increase the success of cancer therapy. The company utilizing proprietary proteomic analysis, we aim to understand the patient's unique response to therapy and overcome one of the major obstacles in clinical oncology today's resistance to therapy. Based on robust scientific infrastructure and a strong IP position, OncoHost is launching an extensive clinical program with leading academic and clinical partners. OncoHost's platform analyzes proteomic changes in blood samples to monitor the dynamics of biological processes induced by the patient in response to given cancer therapy. Response Profiling also identifies potential drug targets, advancing the development of novel therapeutic strategies.OncoHost's profiling platform offers a new layer of information, enabling early identification of non-responsiveness to cancer treatments and the discovery of new targets to overcome treatment resistance. OncoHost was founded in 2017 and is headquartered in Binyamina, Israel.
How much funding has OncoHost raised?
OncoHost has raised $43.0M across 2 rounds on record. The most recent is a Series C of $35.0M announced in May 2022.
When did OncoHost last raise funding?
OncoHost's most recent funding round on record is a Series C of $35.0M, announced in May 2022.
Who founded OncoHost?
FundedIQ lists Yuval Shaked (Founder) at OncoHost.
Who is the CEO of OncoHost?
Ofer Sharon is listed as CEO at OncoHost.
Where is OncoHost headquartered?
OncoHost is based in Binyamina, Hefa, Israel.
How many employees does OncoHost have?
OncoHost is in the 11-50 employee band.
How does OncoHost's funding compare to other Biotechnology startups?
OncoHost's latest round of $35.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's OncoHost Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for OncoHost is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.